All In Biotech

Free tool

FAERS Monitor: Trulicity

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 125469 or its brand name (Trulicity, Dulaglutide). Reports on generic versions are filed under their own applications.

Reports

89,369

Serious

23,531

26% of reports

Hospitalization

11,056

Death reported

1,706

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea10,580
  • injection site pain10,019
  • blood glucose increased9,960
  • diarrhoea6,200
  • vomiting5,949
  • incorrect dose administered5,663
  • inappropriate schedule of product administration3,843
  • drug ineffective3,757
  • weight decreased3,438
  • decreased appetite3,281
  • extra dose administered3,202
  • injection site haemorrhage3,179
  • glycosylated haemoglobin increased2,979
  • abdominal pain upper2,512
  • fatigue2,489

Reports by year received

View as table
YearReports
20111
20124
201414
20151,678
20163,893
20176,225
20187,421
20199,334
202010,676
202112,619
202211,157
20239,512
20247,287
20255,875
20263,673

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,964,790 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
glycosylated haemoglobin increasedSignal2,97931.430.277,310
extra dose administeredSignal3,20220.119.453,651
blood glucose increasedSignal9,96013.112.8106,183
injection site haemorrhageSignal3,1799.79.423,944
injection site painSignal10,0197.97.859,391
incorrect dose administeredSignal5,6636.05.823,051
inappropriate schedule of product administrationSignal3,8435.14.912,522
decreased appetiteSignal3,2813.43.25,413
nauseaSignal10,5803.23.116,161
vomitingSignal5,9493.02.98,026
weight decreasedSignal3,4382.92.84,349
abdominal pain upperSignal2,5122.92.83,105
diarrhoeaSignal6,2002.32.24,514
fatigue2,4890.80.7211
drug ineffective3,7570.70.6649

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.